Guest Editor(s)
-
- Santiago A. Lozano Calderón, MD, PhD
- Department of Orthopaedic Surgery, Musculoskeletal Oncology Service, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Website | E-mail
Special Issue Introduction
Primary bone sarcoma and soft tissue sarcomas are rare neoplasms. Overall, bone sarcomas represent 0.2% of all malignancies, whereas soft tissue sarcomas account for 1% of all malignancies in the US. The most common bone sarcoma in adults is Osteosarcoma, followed by Chondrosarcoma, while in children, Ewing Sarcoma follows Osteosarcoma in prevalence. For soft tissue sarcomas, the most common and prevalent histologies include undifferentiated pleomorphic sarcoma (UPS), Liposarcoma, and Leiomyosarcoma. In general, males are more commonly affected than females. Most patients present with localized disease, but both bone and soft tissue sarcomas have the potential to metastasize primarily to the lungs, bone, liver, and in certain histologic subtypes to the lymphatic nodes.
This Special Issue will focus on the different aspects, techniques, and strategies to manage metastatic and oligometastatic primary bone and soft tissue sarcomas. We are considering pharmacologic, immunotherapeutic, surgical, and radiation approaches for treatment. Target topics include but are not limited to:
- Management of metastatic and oligometastatic disease in Osteosarcoma, Chondrosarcoma, Ewing Sarcoma, and other primary bone sarcomas
- Management of metastatic and oligometastatic disease in Soft Tissue Sarcomas
- Traditional chemotherapy
- Targeted therapies
- Immunotherapy
- Radiofrequency ablation and cryoablation
- Radiation protocols for palliative radiation and definitive treatment of metastasis with radiation therapy
- Surgical management of metastatic disease secondary to sarcoma
Submission Deadline
15 Apr 2023
Journal of Cancer Metastasis and Treatment
